184 related articles for article (PubMed ID: 37327122)
21. Ibrutinib plus Venetoclax for the Treatment of Mantle-Cell Lymphoma.
Tam CS; Anderson MA; Pott C; Agarwal R; Handunnetti S; Hicks RJ; Burbury K; Turner G; Di Iulio J; Bressel M; Westerman D; Lade S; Dreyling M; Dawson SJ; Dawson MA; Seymour JF; Roberts AW
N Engl J Med; 2018 Mar; 378(13):1211-1223. PubMed ID: 29590547
[TBL] [Abstract][Full Text] [Related]
22. Voruciclib, a clinical stage oral CDK9 inhibitor, represses MCL-1 and sensitizes high-risk Diffuse Large B-cell Lymphoma to BCL2 inhibition.
Dey J; Deckwerth TL; Kerwin WS; Casalini JR; Merrell AJ; Grenley MO; Burns C; Ditzler SH; Dixon CP; Beirne E; Gillespie KC; Kleinman EF; Klinghoffer RA
Sci Rep; 2017 Dec; 7(1):18007. PubMed ID: 29269870
[TBL] [Abstract][Full Text] [Related]
23. Sorafenib inhibits cell migration and stroma-mediated bortezomib resistance by interfering B-cell receptor signaling and protein translation in mantle cell lymphoma.
Xargay-Torrent S; López-Guerra M; Montraveta A; Saborit-Villarroya I; Rosich L; Navarro A; Pérez-Galán P; Roué G; Campo E; Colomer D
Clin Cancer Res; 2013 Feb; 19(3):586-97. PubMed ID: 23231952
[TBL] [Abstract][Full Text] [Related]
24. Inhibition of Bcl-2 Synergistically Enhances the Antileukemic Activity of Midostaurin and Gilteritinib in Preclinical Models of FLT3-Mutated Acute Myeloid Leukemia.
Ma J; Zhao S; Qiao X; Knight T; Edwards H; Polin L; Kushner J; Dzinic SH; White K; Wang G; Zhao L; Lin H; Wang Y; Taub JW; Ge Y
Clin Cancer Res; 2019 Nov; 25(22):6815-6826. PubMed ID: 31320594
[TBL] [Abstract][Full Text] [Related]
25. Efficacy of the novel CDK7 inhibitor QS1189 in mantle cell lymphoma.
Choi YJ; Kim DH; Yoon DH; Suh C; Choi CM; Lee JC; Hong JY; Rho JK
Sci Rep; 2019 May; 9(1):7193. PubMed ID: 31076643
[TBL] [Abstract][Full Text] [Related]
26. Inhibition of acylglycerol kinase sensitizes DLBCL to venetoclax via upregulation of FOXO1-mediated BCL-2 expression.
Ning N; Zhang S; Wu Q; Li X; Kuang D; Duan Y; Xia M; Liu H; Weng J; Ba H; Tang Z; Cheng X; Mei H; Huang L; Ao Q; Wang G; Hu Y; Laurence A; Wang J; Wang G; Yang XP
Theranostics; 2022; 12(12):5537-5550. PubMed ID: 35910796
[No Abstract] [Full Text] [Related]
27. Antiproliferative and proapoptotic activity of GUT-70 mediated through potent inhibition of Hsp90 in mantle cell lymphoma.
Jin L; Tabe Y; Kimura S; Zhou Y; Kuroda J; Asou H; Inaba T; Konopleva M; Andreeff M; Miida T
Br J Cancer; 2011 Jan; 104(1):91-100. PubMed ID: 21139584
[TBL] [Abstract][Full Text] [Related]
28. Synergistic activity of BET protein antagonist-based combinations in mantle cell lymphoma cells sensitive or resistant to ibrutinib.
Sun B; Shah B; Fiskus W; Qi J; Rajapakshe K; Coarfa C; Li L; Devaraj SG; Sharma S; Zhang L; Wang ML; Saenz DT; Krieger S; Bradner JE; Bhalla KN
Blood; 2015 Sep; 126(13):1565-74. PubMed ID: 26254443
[TBL] [Abstract][Full Text] [Related]
29. The Therapeutic Synergy of Selinexor and Venetoclax in Mantle Cell Lymphoma Through Induction of DNA Damage and Perturbation of the DNA Damage Response.
Yuan S; Zuo W; Liu T; Fu H
Technol Cancer Res Treat; 2023; 22():15330338231208608. PubMed ID: 37880950
[No Abstract] [Full Text] [Related]
30. Targeted inhibition of PI3Kα/δ is synergistic with BCL-2 blockade in genetically defined subtypes of DLBCL.
Bojarczuk K; Wienand K; Ryan JA; Chen L; Villalobos-Ortiz M; Mandato E; Stachura J; Letai A; Lawton LN; Chapuy B; Shipp MA
Blood; 2019 Jan; 133(1):70-80. PubMed ID: 30322870
[TBL] [Abstract][Full Text] [Related]
31. Impact of elevated anti-apoptotic MCL-1 and BCL-2 on the development and treatment of MLL-AF9 AML in mice.
Anstee NS; Bilardi RA; Ng AP; Xu Z; Robati M; Vandenberg CJ; Cory S
Cell Death Differ; 2019 Jul; 26(7):1316-1331. PubMed ID: 30470795
[TBL] [Abstract][Full Text] [Related]
32. Efficacy of venetoclax in high risk relapsed mantle cell lymphoma (MCL) - outcomes and mutation profile from venetoclax resistant MCL patients.
Zhao S; Kanagal-Shamanna R; Navsaria L; Ok CY; Zhang S; Nomie K; Han G; Hao D; Hill HA; Jiang C; Yao Y; Nastoupil L; Westin J; Fayad L; Nair R; Steiner R; Ahmed S; Samaniego F; Iyer SP; Oriabure O; Chen W; Song X; Zhang J; Badillo M; Moghrabi O; Aranda J; Tang G; Yin CC; Patel K; Medeiros LJ; Li S; Vega F; Thirumurthi S; Xu G; Neelapu S; Flowers CR; Romaguera J; Fowler N; Wang L; Wang ML; Jain P
Am J Hematol; 2020 Jun; 95(6):623-629. PubMed ID: 32239765
[TBL] [Abstract][Full Text] [Related]
33. Exploiting PRMT5 as a target for combination therapy in mantle cell lymphoma characterized by frequent ATM and TP53 mutations.
Che Y; Liu Y; Yao Y; Hill HA; Li Y; Cai Q; Yan F; Jain P; Wang W; Rui L; Wang M
Blood Cancer J; 2023 Feb; 13(1):27. PubMed ID: 36797243
[TBL] [Abstract][Full Text] [Related]
34. Long-term Follow-up of Patients with Relapsed or Refractory Non-Hodgkin Lymphoma Treated with Venetoclax in a Phase I, First-in-Human Study.
Davids MS; Roberts AW; Kenkre VP; Wierda WG; Kumar A; Kipps TJ; Boyer M; Salem AH; Pesko JC; Arzt JA; Mantas M; Kim SY; Seymour JF
Clin Cancer Res; 2021 Sep; 27(17):4690-4695. PubMed ID: 34083230
[TBL] [Abstract][Full Text] [Related]
35. Arsenic trioxide rewires mantle cell lymphoma response to bortezomib.
Zhao LL; Liu YF; Peng LJ; Fei AM; Cui W; Miao SC; Hermine O; Gressin R; Khochbin S; Chen SJ; Wang J; Mi JQ
Cancer Med; 2015 Nov; 4(11):1754-66. PubMed ID: 26310857
[TBL] [Abstract][Full Text] [Related]
36. Targeting MCL-1 dysregulates cell metabolism and leukemia-stroma interactions and resensitizes acute myeloid leukemia to BCL-2 inhibition.
Carter BZ; Mak PY; Tao W; Warmoes M; Lorenzi PL; Mak D; Ruvolo V; Tan L; Cidado J; Drew L; Andreeff M
Haematologica; 2022 Jan; 107(1):58-76. PubMed ID: 33353284
[TBL] [Abstract][Full Text] [Related]
37. Transcription and translation are primary targets of Pim kinase inhibitor SGI-1776 in mantle cell lymphoma.
Yang Q; Chen LS; Neelapu SS; Miranda RN; Medeiros LJ; Gandhi V
Blood; 2012 Oct; 120(17):3491-500. PubMed ID: 22955922
[TBL] [Abstract][Full Text] [Related]
38. Modulation of BCL-2 in Both T Cells and Tumor Cells to Enhance Chimeric Antigen Receptor T-cell Immunotherapy against Cancer.
Lee YG; Guruprasad P; Ghilardi G; Pajarillo R; Sauter CT; Patel R; Ballard HJ; Hong SJ; Chun I; Yang N; Amelsberg KV; Cummins KD; Svoboda J; Gill S; Chong EA; North K; Church SE; Fraietta JA; Chang WJ; Lacey SF; Lu XM; Zhang Y; Whig K; Schultz DC; Cherry S; Gerson J; Schuster SJ; Porazzi P; Ruella M
Cancer Discov; 2022 Oct; 12(10):2372-2391. PubMed ID: 35904479
[TBL] [Abstract][Full Text] [Related]
39. Bcl-2 Family Members Bcl-xL and Bax Cooperatively Contribute to Bortezomib Resistance in Mantle Cell Lymphoma.
Luanpitpong S; Janan M; Yosudjai J; Poohadsuan J; Chanvorachote P; Issaragrisil S
Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430955
[TBL] [Abstract][Full Text] [Related]
40. Concurrent inhibition of PI3K and mTORC1/mTORC2 overcomes resistance to rapamycin induced apoptosis by down-regulation of Mcl-1 in mantle cell lymphoma.
Müller A; Zang C; Chumduri C; Dörken B; Daniel PT; Scholz CW
Int J Cancer; 2013 Oct; 133(8):1813-24. PubMed ID: 23580240
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
